Next Article in Journal
Applications of a Specialty Bicuspid Aortic Valve Program: Clinical Continuity and Translational Collaboration
Previous Article in Journal
Treatment of Infected Tibial Non-Unions with Ilizarov Technique: A Case Series
Previous Article in Special Issue
Deregulation of the Purine Pathway in Pre-Transplant Liver Biopsies Is Associated with Graft Function and Survival after Transplantation
Review

Cholangiocarcinoma as an Indication for Liver Transplantation in the Era of Transplant Oncology

1
Hepatobiliary Surgery and Liver Transplantation, Padua University Hospital, 35100 Padua, Italy
2
Multivisceral Transplant Unit and Gastroenterology, Padua University Hospital, 35100 Padua, Italy
3
Multi-Organ Transplant and HPB Surgical Oncology, Division of General Surgery, University Health Network, Department of Surgery, University of Toronto, Toronto, ON M5G 2N2, Canada
4
Surgical Pathology & Cytopathology Unit, Department of Medicine, Padua University Hospital, 35100 Padua, Italy
*
Author to whom correspondence should be addressed.
These authors contributed equally to this work.
J. Clin. Med. 2020, 9(5), 1353; https://doi.org/10.3390/jcm9051353
Received: 2 April 2020 / Revised: 20 April 2020 / Accepted: 24 April 2020 / Published: 5 May 2020
(This article belongs to the Special Issue Liver Transplantation)
Cholangiocarcinoma (CCA) arises from the biliary tract epithelium and accounts for 10–15% of all hepatobiliary malignancies. Depending on anatomic location, CCA is classified as intrahepatic (iCCA), perihilar (pCCA) and distal (dCCA). The best treatment option for pCCA is liver resection and when a radical oncological surgery is obtained, 5-year survival rate are around 20–40%. In unresectable patients, following a specific protocol, liver transplantation (LT) for pCCA showed excellent long-term disease-free survival rates. Fewer data are available for iCCA in LT setting. Nevertheless, patients with very early unresectable iCCA appear to achieve excellent outcomes after LT. This review aims to evaluate existing evidence to define the current role of LT in the management of patients with CCA. View Full-Text
Keywords: liver transplantation; cholangiocarcinoma; surgery liver transplantation; cholangiocarcinoma; surgery
Show Figures

Figure 1

MDPI and ACS Style

Gringeri, E.; Gambato, M.; Sapisochin, G.; Ivanics, T.; Lynch, E.N.; Mescoli, C.; Burra, P.; Cillo, U.; Russo, F.P. Cholangiocarcinoma as an Indication for Liver Transplantation in the Era of Transplant Oncology. J. Clin. Med. 2020, 9, 1353. https://doi.org/10.3390/jcm9051353

AMA Style

Gringeri E, Gambato M, Sapisochin G, Ivanics T, Lynch EN, Mescoli C, Burra P, Cillo U, Russo FP. Cholangiocarcinoma as an Indication for Liver Transplantation in the Era of Transplant Oncology. Journal of Clinical Medicine. 2020; 9(5):1353. https://doi.org/10.3390/jcm9051353

Chicago/Turabian Style

Gringeri, Enrico, Martina Gambato, Gonzalo Sapisochin, Tommy Ivanics, Erica N. Lynch, Claudia Mescoli, Patrizia Burra, Umberto Cillo, and Francesco P. Russo. 2020. "Cholangiocarcinoma as an Indication for Liver Transplantation in the Era of Transplant Oncology" Journal of Clinical Medicine 9, no. 5: 1353. https://doi.org/10.3390/jcm9051353

Find Other Styles
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map by Country/Region

1
Back to TopTop